GlassScriptPhysician profile
Dana J Schultz
NPI 1720087042
$11,351.66
in general payments reported to CMS, 2019-2025
27 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,618 · 2020: $433 · 2021: $4,631 · 2022: $1,291 · 2023: $932 · 2024: $445.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,372 · Education: $5.17.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,372.46 |
| Education | $5.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $7,772.97 | 2019-2024 | Qelbree, Qelbree |
| Tris Pharma INC | $777.56 | 2019-2024 | Dyanavel Xr |
| Corium, LLC | $423.39 | 2021-2024 | Azstarys |
| Neos Therapeutics, LP | $380.60 | 2019-2024 | Adzenys Xr-Odt |
| Takeda Pharmaceuticals U.S.A., INC. | $293.41 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $251.61 | 2019-2024 | Vaxneuvance, Vaxelis, Gardasil 9 |
| Pfizer INC. | $230.18 | 2019-2024 | |
| Sanofi Pasteur INC. | $167.31 | 2020-2023 | |
| Glaxosmithkline, LLC. | $150.36 | 2019-2023 | Bexsero |
| Ironshore Pharmaceuticals INC. | $148.65 | 2020-2024 | Jornay Pm |
| Adlon Therapeutics L.P. | $133.78 | 2019-2021 | |
| Cranial Technologies, INC | $129.82 | 2019-2023 | Doc Band |
| Seqirus USA INC | $90.52 | 2022-2024 | Flucelvax Quadrivalent, Flucelvax |
| Vertical Pharmaceuticals, LLC | $79.64 | 2019-2020 | |
| Kaleo, INC. | $76.76 | 2020-2023 | Auvi-Q |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ultragenyx Pharmaceutical INC. | $45.53 | 2022 | |
| Shire North American Group INC | $27.63 | 2019 | |
| Arbor Pharmaceuticals, INC. | $26.98 | 2019 | |
| Rhodes Pharmaceuticals L.P. | $21.21 | 2019 | |
| Genentech USA, INC. | $21.17 | 2020 | |
| Sobi, INC | $21.07 | 2022 | |
| Biogen, INC. | $18.61 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $15.50 | 2022 | |
| Roche Diagnostics Corporation | $15.45 | 2019 | |
| Noven Therapeutics, LLC | $15.24 | 2024 | Xelstrym |
| Mylan Pharmaceuticals INC. | $13.33 | 2019 | |
| Aytu Biopharma, INC. | $3.38 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dana Schultz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.